Vaccine stocks are cracking under intense selling pressure, and one small developer with no control over its own commercial fate is bearing the worst of it. Whether its big-pharma partner can change ...
Novavax has had a volatile few years, and the share price history raises a straightforward question for you as an investor.
In an interview with Labiotech, Jacobs discussed the decisions behind Novavax’s transformation, the economics of its new ...
Fintel on MSN
Novavax, Inc. earns $125 million milestone as Sanofi launches phase 3 influenza-COVID-19 combination vaccine trial
Novavax, Inc. reported that on October 28, 2026 Sanofi Pasteur Inc. dosed the fifth patient in its Phase 3 influenza-COVID-19 ...
Zacks Investment Research on MSN
Investors heavily search Novavax, Inc. (NVAX): Here is what you need to know
Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...
Novavax ( ) has provided an announcement. On October 28, 2026, Sanofi Pasteur dosed the fifth patient in its Phase 3 influenza–COVID-19 combination vaccine trial in the European ...
A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as low. That reversal in sentiment lands hardest on Novavax (NASDAQ:NVAX), ...
Novavax President and Chief Executive Officer John C. Jacobs said the partnership has generated more than $1 billion in revenue for Novavax to date. He added that the Phase 3 trial represents progress ...
Novavax’s shares are extremely volatile and have had 46 moves greater than 5% over the last year. But moves this big are rare ...
After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who ...
Novavax, Inc.'s valuation remains too high given its reliance on one-off revenues, uncertain royalties, and a complex Sanofi partnership. The company's Q1 2025 earnings were boosted by non-recurring ...
Novavax (Nasdaq: NVAX) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results